ArticleInflammopharmacology2018
Probiotic mixture of Lactobacillus and Bifidobacterium alleviates systemic adiposity and inflammation in non-alcoholic fatty liver disease rats through Gpr109a and the commensal metabolite butyrate.
Article in Inflammopharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Hepatoprotection of Probiotics Against Non-Alcoholic Fatty Liver DiseaseFrontiers in nutrition · 2022Pooled it
- Modulating the Gut-Liver Axis: Anti-Inflammatory Mechanisms of Probiotics and Prebiotics in MASLD.Probiotics and antimicrobial proteins · 2026Review
- Effects of U62631.5 on short-chain fatty acid receptor 41(GPR41) and the related intestinal bacterium Butyricicoccus pullicaecorum after fecal bacterial transplantation in nonalcoholic fatty liver disease.BMC microbiology · 2026Article
- Interplay between intestinal permeability and metabolic dysfunction-associated steatotic liver disease: Could there be a role for extra virgin olive oil consumption?World journal of hepatology · 2025Review
- Phytobacter sp. RSE02 is a rice seed endophytic plant probiotic bacterium with human probiotic features and cholesterol-lowering ability.Scientific reports · 2025Article
- Decreased gut microbiome-derived indole-3-propionic acid mediates the exacerbation of myocardial ischemia/reperfusion injury following depression via the brain-gut-heart axis.Redox biology · 2025Article
- Hepatoprotective effect of lotus leaf against non-alcoholic fatty liver disease in rats via alteration of AMPK/SIRT1 and Nrf2/HO-1 signaling pathway.Acta cirurgica brasileira · 2025Article
- Fecal fermentation behaviors of Konjac glucomannan and its impacts on human gut microbiota.Food chemistry: X · 2024Article
- The role of intestinal flora in metabolic dysfunction-associated steatotic liver disease and treatment strategies.Frontiers in medicine · 2024Review
- Meta-analysis of the effects of probiotics on hyperlipidemia.Current research in food science · 2024Article
- Article
- Probiotics, prebiotics, and synbiotics in nonalcoholic fatty liver disease and alcohol-associated liver disease.American journal of physiology. Gastrointestinal and liver physiology · 2023Review
- Article
- Butyrate to combat obesity and obesity-associated metabolic disorders: Current status and future implications for therapeutic use.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2022Review
- Astaxanthin FromFrontiers in nutrition · 2022Article
- Synbiotic (Lactiplantibacillus pentosus GSSK2 and isomalto-oligosaccharides) supplementation modulates pathophysiology and gut dysbiosis in experimental metabolic syndrome.Scientific reports · 2021Article
- Probiotics and Prebiotics as a Strategy for Non-Alcoholic Fatty Liver Disease, a Narrative Review.Foods (Basel, Switzerland) · 2021Review
- Distinctive gut microbial dysbiosis between chronic alcoholic fatty liver disease and metabolic-associated fatty liver disease in mice.Experimental and therapeutic medicine · 2021Article
- Is butyrate a natural alternative to dexamethasone in the management of CoVID-19?F1000Research · 2021Review
- The Gut Microbiome and Alcoholic Liver Disease: Ethanol Consumption Drives Consistent and Reproducible Alteration in Gut Microbiota in Mice.Life (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimsThe study explored the systemic adiposity and inflammation through Gpr109a and the commensal metabolite butyrate during the treatment of non-alcoholic fatty liver disease rats with the probiotic mixture of Lactobacillus and Bifidobacterium for 16 weeks.
methodsFifteen male SD rats were randomly divided into three groups of five rats each: normal control group (basal feed), high-fat diet (HFD) feeding group (83% basal feed + 10% lard oil + 5% sucrose + 1.5% cholesterol + 0.5% cholate), and probiotic mixture intervention group (HFD + 0.6 g kg
resultsCompared with HFD group, probiotic mixture significantly reduced body weight and the levels of serum FFA, TG, ALT, IL-1β, and IL-18 (P < 0.05). The levels of Gpr109a and the commensal metabolite butyrate also changed significantly (P < 0.05).
conclusionsProbiotic mixture might inhibit systemic adiposity and inflammation through Gpr109a and the commensal metabolite butyrate in response to the insult of HFD.
Indexed as
Identifiers
29633106What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.